Equillium Announces Interim Analysis From Phase 3 EQUATOR Study Of Itolizumab In Acute Graft-Versus-Host Disease
Portfolio Pulse from Benzinga Newsdesk
Equillium, Inc. announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). The IDMC recommended the continuation of the trial based on safety and efficacy assessments. This triggers a 90-day period for Ono Pharmaceutical Co., Ltd. to exercise its option to acquire Equillium's rights to itolizumab for JPY 5 billion plus potential milestone payments.
August 06, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Equillium received a positive recommendation from the IDMC for its Phase 3 EQUATOR study of itolizumab in aGVHD, leading to a 90-day period for Ono Pharmaceutical to potentially acquire rights for JPY 5 billion plus milestone payments.
The positive IDMC recommendation is a significant milestone for Equillium's Phase 3 EQUATOR study, indicating the trial's continuation without modifications. This news is likely to boost investor confidence and positively impact the stock price in the short term. Additionally, the potential acquisition by Ono Pharmaceutical adds further value.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100